Clinical trials: Advanced Cancer
Melanoma
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain.
- Trial name
- NCT01619774
- Testing
- GSK2118436, GSK1120212
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967889
- Testing
- gene expression analysis, protein analysis, biologic sample preservation procedure
- Where
- United Kingdom
- Sponsor
- Cancer Research UK
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer.
- Conditions
- Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
- Trial name
- NCT00707473
- Testing
- Carboplatin, Chemoradiotherapy, Cisplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasm
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein.
- Trial name
- NCT01697527
- Testing
- aldesleukin, fludarabine phosphate, cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma, Ovarian Neoplasms
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment.
- Conditions
- Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00443196
- Testing
- MiCK Assay
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pierian Biosciences
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Lung Cancer
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and…
- Trial name
- NCT07272057
- Testing
- SGLT-2 inhibitor
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Diaphragm Disease
Intra-operative Visual Examination at IDS
Complete disease removal has the greatest impact in the treatment of advanced ovarian cancer, both during primary debulking surgery (PDS) and interval debulking surgery (IDS), but, contrarily to PDS, no consensus exist on the…
- Trial name
- VIPER (NCT04444934)
- Testing
- histological examination
- Where
- Italy
- Volunteers
- 155 people
- Sponsor
- Catholic University of the Sacred Heart
Advanced Cancers
Azacytidine and Valproic Acid in Patients With Advanced Cancers
Primary Objective: 1. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer. Secondary Objectives: 1.
- Trial name
- NCT00496444
- Testing
- Azacitidine, Valproic Acid
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Peritoneal Cancer
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis.
- Trial name
- NCT00491855
- Testing
- Bevacizumab, Oxaliplatin, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
SMARCA4-Deficient Tumor, NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer
This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).
- Trial name
- NCT07121387
- Where
- China
- Volunteers
- 221 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma
- Trial name
- NCT03210714
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Study Of ATRN-119 In Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid…
- Trial name
- ABOYA-119 (NCT04905914)
- Testing
- ATRN-119
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Aprea Therapeutics
Urothelial Carcinoma
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or…
- Trial name
- NCT03330886
- Testing
- Atezolizumab
- Where
- Argentina
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Soft Tissue Sarcoma, Child
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and…
- Trial name
- NCT07528079
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.